Evidence is mounting that endocrine-disrupting chemicals such as phthalates, can be linked to a number of diseases and conditions. Endocrine disruptors act by interfering with the biosynthesis, secretion, action or metabolism of naturally occurring hormones.
Fournier’s gangrene is a newly identified safety concern in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors. Physicians prescribing these agents should be aware of this possible complication and have a high index of suspicion to recognise it in its early stages.
Negative pressure wound therapy has greatly improved the healing process by ensuring that pressure is distributed uniformly across the incision and zone of injury and reducing the need for dressing changes.